S. Peter Kang - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas , Igor Puzanov , Reinhard Dummer +33 more

2015 The Lancet Oncology 1528 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid , Caroline Robert , Adil Daud +23 more

In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rat...

2013 New England Journal of Medicine 3352 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,880
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-8606-2979

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.